<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02185794</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-338-1121</org_study_id>
    <nct_id>NCT02185794</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-9857 in Subjects With Chronic Hepatitis C Virus Infection</brief_title>
  <official_title>Phase 1b, Randomized, Double-Blind, Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-9857 in Subjects With Chronic Hepatitis C Virus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability, and antiviral activity of GS-9857 alone or
      with sofosbuvir (SOF)/GS-5816 fixed dose combination (FDC) in adults with genotypes 1, 2, 3,
      or 4 hepatitis C virus (HCV) infection. All participants will be monitored for up to 48 weeks
      after the last dose to monitor for persistence of viral mutations.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events, laboratory abnormalities, 12-lead electrocardiogram abnormalities and interval measurements, and vital sign measurements</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>This composite endpoint will measure the safety and tolerability profile of GS-9857.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in plasma HCV RNA (log10 IU/mL)</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Categorical change from baseline in HCV RNA (&lt; 1, ≥ 1 to &lt;2, ≥ 2 to &lt;3, or ≥ 3 log10 IU/mL reductions)</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Hepatitis C Virus Infection</condition>
  <arm_group>
    <arm_group_label>Genotype 1a GS-9857±placebo (Cohort 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with genotype 1a HCV infection will receive GS-9857 up to 300 mg with or without placebo to match GS-9857 under fasted conditions for 3 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype 3 GS-9857±placebo (Cohort 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with genotype 3 HCV infection will receive GS-9857 up to 300 mg with or without placebo to match GS-9857 under fasted conditions for 3 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype 2 GS-9857±placebo (Cohort 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with genotype 2 HCV infection will receive GS-9857 up to 300 mg with or without placebo to match GS-9857 under fasted conditions for 3 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GS-9857 600 mg (Cohorts 4-9)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with genotypes 1a, 1b, 2, 3, or 4 HCV infection will receive GS-9857 up to 600 mg under fasted or fed conditions for 3 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GS-9857+SOF/GS-5816 (Cohort 10)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with any genotype HCV infection will receive GS-9857 100 mg on Day 1 and GS-9857 100 mg plus SOF/GS-5816 on Days 2 and 3 with either a light or moderate-fat meal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-9857</intervention_name>
    <description>GS-9857 tablets administered orally once daily</description>
    <arm_group_label>Genotype 1a GS-9857±placebo (Cohort 1)</arm_group_label>
    <arm_group_label>Genotype 3 GS-9857±placebo (Cohort 2)</arm_group_label>
    <arm_group_label>Genotype 2 GS-9857±placebo (Cohort 3)</arm_group_label>
    <arm_group_label>GS-9857 600 mg (Cohorts 4-9)</arm_group_label>
    <arm_group_label>GS-9857+SOF/GS-5816 (Cohort 10)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to match GS-9857</intervention_name>
    <description>Placebo to match GS-9857 tablets administered orally once daily</description>
    <arm_group_label>Genotype 1a GS-9857±placebo (Cohort 1)</arm_group_label>
    <arm_group_label>Genotype 3 GS-9857±placebo (Cohort 2)</arm_group_label>
    <arm_group_label>Genotype 2 GS-9857±placebo (Cohort 3)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOF/GS-5816</intervention_name>
    <description>Sofosbuvir (SOF) 400 mg/GS-5816 100 mg FDC tablet administered orally once daily</description>
    <arm_group_label>GS-9857+SOF/GS-5816 (Cohort 10)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic genotype 1-4 HCV infection

          -  For Cohorts 1-9, HCV RNA ≥ 100,000 IU/mL at screening (no HCV RNA restriction for
             Cohort 10)

          -  Screening laboratory values within defined thresholds

          -  Use of two effective contraception methods if female of childbearing potential or
             sexually active male

        Exclusion Criteria:

          -  Pregnant or nursing female or male with pregnant female partner

          -  Presence of cirrhosis

          -  Prior exposure to approved or experimental HCV Protease Inhibitors

          -  Co-infection with HIV or hepatitis B virus (HBV)

          -  Current or prior history of clinical hepatic decompensation

          -  Chronic use of systemic immunosuppressive agents

          -  History of clinically significant illness or any other medical disorder that may
             interfere with subject treatment, assessment or compliance with the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luisa Stamm, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Juan</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2014</study_first_submitted>
  <study_first_submitted_qc>July 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2014</study_first_posted>
  <last_update_submitted>October 8, 2015</last_update_submitted>
  <last_update_submitted_qc>October 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCV genotype 1 (GT-1)</keyword>
  <keyword>HCV genotype 2 (GT-2)</keyword>
  <keyword>HCV genotype 3 (GT-3)</keyword>
  <keyword>HCV genotype 4 (GT-4)</keyword>
  <keyword>HCV</keyword>
  <keyword>Sustained Virologic Response</keyword>
  <keyword>Direct Acting Antiviral</keyword>
  <keyword>Combination Therapy</keyword>
  <keyword>Open Label</keyword>
  <keyword>Hepatitis</keyword>
  <keyword>Hepatitis, Chronic</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>Hepatitis C, Chronic</keyword>
  <keyword>Liver Diseases</keyword>
  <keyword>Digestive System Diseases</keyword>
  <keyword>Hepatitis, Viral, Human</keyword>
  <keyword>Virus Diseases</keyword>
  <keyword>Enterovirus Infections</keyword>
  <keyword>Picornaviridae Infections</keyword>
  <keyword>RNA Virus Infections</keyword>
  <keyword>Flaviviridae Infections</keyword>
  <keyword>Antiviral Agents</keyword>
  <keyword>Anti-Infective Agents</keyword>
  <keyword>Therapeutic Uses</keyword>
  <keyword>Pharmacologic Actions</keyword>
  <keyword>Antimetabolites</keyword>
  <keyword>Molecular Mechanisms of Pharmacological Action</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antiviral Agents</mesh_term>
    <mesh_term>Molecular Mechanisms of Pharmacological Action</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

